Abbvie Inc.

Abbott Laboratories Corporation

Abbvie Deutschland Gmbh and Co Kg

Abbott Gmbh & Co Kg

Jijie Gu

Chung-Ming Hsieh

Yingchun Li

Tariq Ghayur

Jonathan A Hickson

Maria Harris

Lorenzo Benatuil

Susan Elizabeth Morgan-Lappe

Ravi Chari

Yuliya Kutskova

Supriya Gupta

Camellia Zamiri

Dominic J Ambrosi

Erwin R Boghaert

Louie Naumovski

Susan E Lappe

Deanna L Haasch

Xianhua Cao

Zhihong Liu

Ulrich Ebert

Martin Schmidt

Reinhold Mueller

Feng Dong

Volker Nimmrich

Carrie Goodreau

Peter C Isakson

John E Harlan

Enrico L Digiammarino

Gerard B Fox

Ralf Loebbert

Zhen Wu

Feng Luo

Sonal Saluja

Ming-Jiu Chen

Jochen G Salfeld

Anca Clabbers

Junjian Liu

Michael McPherson

Lucia Eaton

Diana Bowley

Matthew Rieser

Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.

Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof

Engineered monovalent binding proteins that bind to one or more ligands (such as an antigen) via one binding domain are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.

Monovalent binding proteins

Binding proteins that bind one or more of VEGF, PDGF and/or their receptors, including antibodies, CDR-grafted antibodies, humanized antibodies, binding fragments, fusion proteins, and bispecific or multispecific proteins thereof are disclosed. Also disclosed are methods of making and using the binding proteins.

Antibodies against platelet-derived growth factor (PDGF)

The present invention relates to improved methods for antibody engineering, e.g., humanization. In particular, the disclosure provides a high-throughput antibody humanization process that can be automated by computer-implementation.

High-throughput antibody humanization

Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.

Therapeutic DLL4 binding proteins

DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid &#x3b2; and advanced glycation-end-products.

Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof

Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity.

Engineered multivalent and multispecific binding proteins that bind IL-1&#x3b2; and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.

Dual specific binding proteins directed against IL-1 and/or IL-17

Dual specific binding proteins directed against IL-1&#x3b2; and/or IL-17

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

Prostaglandin E2 dual variable domain immunoglobulins and uses thereof

Dual variable domain immunoglobulins and uses thereof

Growing community of inventors

Shrewsbury, MA, United States of America

Jijie Gu